What is AEON's health score?

AEON Biopharma, Inc. (AEON) has a TradeApes health score of 47 out of 100, rated Mixed. This composite score evaluates financial strength, operating trends, valuation, capital allocation, and risk factors.

What is AEON's estimated fair value?

Based on our 5-year discounted cash flow model, AEON Biopharma, Inc.'s estimated fair value is $N/A per share. This is a model estimate, not a price target or investment recommendation.

Is AEON undervalued or overvalued?

Our model currently rates AEON as Inconclusive. This assessment combines health metrics, valuation multiples, and market sentiment. Individual investors should conduct their own due diligence.

To Unlock Full Report

3 free score cards remaining

AEON Biopharma, Inc. (AEON)

Healthcare Inconclusive inconclusive mixed

$0.3

Updated: 2026-07-16

TradeApes Score

Financial Strength

45 Mixed

Operating Trend

50 Mixed

Relative Value

48 Mixed

Capital Allocation

30 Weak

Risk Management

65 Healthy

Key Findings

+ Low leverage — net debt/EBITDA below 1×

Unlock Full Report →

− Significant dilution — share count up more than 5% year over year

Unlock Full Report →

Industry Related Stocks

ASCENTAGE PHARMA GROUP INTERNATIONAL (AAPG) Aardvark Therapeutics, Inc. (AARD) Abivax S.A. (AAVXF) Ascend Wellness Holdings, Inc. (AAWH) AbbVie Inc. (ABBV) AbCellera Biologics Inc. (ABCL)

See all Healthcare stocks →

TradeApes provides financial data, analytics, and research tools. TradeApes is not a registered investment adviser, broker-dealer, or tax advisor. The information presented is for educational and informational purposes only and does not constitute investment, financial, or tax advice.

11 sector-leading stocks delivered to your inbox every Sunday. Free.

No spam. Unsubscribe anytime.